China Pharmaceuticals and Healthcare Report Q1 2016

China Pharmaceuticals and Healthcare Report Q1 2016

Includes 3 FREE quarterly updates

BMI View:

Provincial and county level healthcare markets in China will become increasingly important for multinational pharmaceutical companies. This follows government reforms to channel patient volumes to local medical facilities as well as the saturation of the major hospital markets in tier one cities. Foreign firms seeking to make this shift will have to navigate the significant variances across provinces, strong competition from local drugmakers as well as the low levels of disease awareness among the rural populace.


Headline

Expenditure Projections


- Pharmaceuticals: CNY608bn (USD99bn) in 2014 to CNY688bn (USD108bn) by 2015; +13.0% in local currency terms and +9.2% in USD terms.
- Healthcare: CNY3,594bn (USD583bn) in 2014 to CNY4,079bn (USD640bn) in 2015; +13.5% in local currency and +9.6% in USD terms.
BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (China 2013-2019) . . 7
SWOT 9
Industry Forecast .. 11
Pharmaceutical Market Forecast . 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (China 2011-2019) . . 14
Healthcare Market Forecast . 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (China 2011-2019) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (China 2011-2019) . . 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (China 2011-2019) . 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (China 2011-2019) . 20
Patented Drug Market Forecast .. 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (China 2011-2019) . 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (China 2011-2019) . . 24
OTC Drug Market Forecast .. 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (China 2011-2019) 27
Pharmaceutical Trade Forecast .. 28
Table: Pharmaceutical Trade Data And Forecasts (China 2013-2019) . 30
Table: Pharmaceutical Trade Data And Forecasts local currency (China 2013-2019) 30
Industry Risk Reward Index 31
Asia Pacific Risk/Reward Index 31
China Risk/Reward Index .. 38
Rewards .. 38
Risks . 38
Regulatory Review 40
Regulatory Regime 40
Table: Important China GMP Deadlines 44
Intellectual Property Issues . 46
Pricing Regime .. 51
Reimbursement Regime 57
Market Overview 61
Healthcare Sector . 61
Table: Healthcare Resources (China 2009-2014) 64
Table: Healthcare Personnel (China 2009-2014) 64
Table: Healthcare Activity (China 2009-2014) 65
Research & Development 72
Table: Selected List Of MNC With R&D Bases In China . 72
Table: Selected List Of Collaboration In R&D Operations In China . 76
Clinical Trials 77
Table: Estimated Number Of New Cases Of Cancer In China . . 81
Competitive Landscape . 82
Research-Based Industry . 82
Table: Companies Represented by RDPAC 82
Table: Multinational Market Activity . 83
Generic Drugmakers 84
Table: Top 20 China/Hong Kong-Based Pharmaceutical Companies According To Market Capitalisation 85
Traditional Chinese Medicines .. 85
Pharmaceutical Distribution .. 88
Company Profile . 90
AstraZeneca . 90
Bayer . 95
China Shijiazhuang Pharmaceutical Group .. 99
Eli Lilly .. 101
GlaxoSmithKline .. 104
North China Pharmaceutical Corporation .. 109
Novartis .. 112
Merck & Co 116
Merck KGaA . 119
Pfizer .. 122
Roche .. 125
Sanofi .. 129
Shanghai Pharmaceutical .. 133
Sinopharm .. 136
Demographic Forecast 139
Table: Population Headline Indicators (China 1990-2025) . 140
Table: Key Population Ratios (China 1990-2025) . 140
Table: Urban/Rural Population & Life Expectancy (China 1990-2025) 141
Table: Population By Age Group (China 1990-2025) . 141
Table: Population By Age Group % (China 1990-2025) . 142
Glossary 144
Methodology .. 146
Pharmaceutical Expenditure Forecast Model .. 146
Healthcare Expenditure Forecast Model 146
Notes On Methodology .. 147
Risk/Reward Index Methodology . 148
Index Overview 149
Table: Pharmaceutical Risk/Reward Index Indicators 149
Indicator Weightings . 150
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.

Looking for something else?